Blood Metabolomic Signatures to Identify Bacterial Infection in Patients with Decompensated Cirrhosis.


Journal

Journal of gastrointestinal and liver diseases : JGLD
ISSN: 1842-1121
Titre abrégé: J Gastrointestin Liver Dis
Pays: Romania
ID NLM: 101272825

Informations de publication

Date de publication:
19 03 2022
Historique:
received: 24 09 2021
accepted: 27 01 2022
entrez: 20 3 2022
pubmed: 21 3 2022
medline: 28 4 2022
Statut: epublish

Résumé

Bacterial infections are associated with high mortality rates in patients with decompensated cirrhosis. Early diagnosis with the available diagnostic tools is challenging. Metabolomics is a novel technique with a widespread application in hepatology. The aims of our study were to find new biomarkers for decompensated cirrhosis and for those with overlapping bacterial infections. 43 patients with compensated and 54 patients with decompensated cirrhosis were enrolled in the study. In patients with decompensation, a complete infectious workup was performed at admission. Blood and ascitic fluid were collected and stored at -80° C until performing the metabolomic analysis. Statistical analysis was performed using the Metaboanalyst 4.0 software. 36 patients (66%) in the decompensated group were infected. Among them, 15 had multiple infections; thus, finally, 52 infections were diagnosed. The main metabolic pathways affected in patients with decompensated cirrhosis were those related to lipid metabolism, involving acylcarnitines, stearic acid derivatives, and 12/15 HETE-GABA. N-oleoyl ethanolamine was the most promising biomarker for bacterial infection diagnosis. Moreover, prostaglandin E2/D2/H2 and N-oleoyl alanine levels were higher in Gram- positive infections and ceramides (d16:2/18:0), in Gram-negative infections, respectively. L-phenylalanine (m/z=166.09) and lysophosphatidylethanolamine (18:3/0:0) were the two most relevant identified ascitic biomarkers for spontaneous bacterial peritonitis diagnosis. The lipid and energetic metabolic pathways were the most affected in patients with decompensated cirrhosis and those with overlapping infections.

Sections du résumé

BACKGROUND AND AIMS
Bacterial infections are associated with high mortality rates in patients with decompensated cirrhosis. Early diagnosis with the available diagnostic tools is challenging. Metabolomics is a novel technique with a widespread application in hepatology. The aims of our study were to find new biomarkers for decompensated cirrhosis and for those with overlapping bacterial infections.
METHODS
43 patients with compensated and 54 patients with decompensated cirrhosis were enrolled in the study. In patients with decompensation, a complete infectious workup was performed at admission. Blood and ascitic fluid were collected and stored at -80° C until performing the metabolomic analysis. Statistical analysis was performed using the Metaboanalyst 4.0 software.
RESULTS
36 patients (66%) in the decompensated group were infected. Among them, 15 had multiple infections; thus, finally, 52 infections were diagnosed. The main metabolic pathways affected in patients with decompensated cirrhosis were those related to lipid metabolism, involving acylcarnitines, stearic acid derivatives, and 12/15 HETE-GABA. N-oleoyl ethanolamine was the most promising biomarker for bacterial infection diagnosis. Moreover, prostaglandin E2/D2/H2 and N-oleoyl alanine levels were higher in Gram- positive infections and ceramides (d16:2/18:0), in Gram-negative infections, respectively. L-phenylalanine (m/z=166.09) and lysophosphatidylethanolamine (18:3/0:0) were the two most relevant identified ascitic biomarkers for spontaneous bacterial peritonitis diagnosis.
CONCLUSIONS
The lipid and energetic metabolic pathways were the most affected in patients with decompensated cirrhosis and those with overlapping infections.

Identifiants

pubmed: 35306561
doi: 10.15403/jgld-4034
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-47

Auteurs

Petra Fischer (P)

Gastroenterology and Hepatology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca. . fischerpetra23@yahoo.com.

Stanca Pandrea (S)

Microbiology Department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. stanca_lucia_pandrea@yahoo.com.

Crina Grigoras (C)

Gastroenterology and Hepatology Department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. crina.anca@gmail.com.

Horia Stefanescu (H)

Gastroenterology and Hepatology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca; Hepatology Deptartment, Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Cluj- Napoca, Romania. drhstefanescu@gmail.com.

Oana Farcau (O)

Gastroenterology and Hepatology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca; Hepatology Deptartment, Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Cluj- Napoca, Romania. oana.farcau@gmail.com.

Cristian Tefas (C)

Gastroenterology and Hepatology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca; Hepatology Deptartment, Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Cluj- Napoca, Romania. tefascristian@gmail.com.

Carmen Socaciu (C)

Department of Chemistry, Biochemistry and Molecular Biology, University of Agricultural Sciences and Veterinary Medicine, Cluj Napoca, Romania. carmen.socaciu@usamvcluj.ro.

Bogdan Procopet (B)

Gastroenterology and Hepatology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca; Hepatology Deptartment, Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Cluj- Napoca, Romania. bogdanprocopet@gmail.com.

Daniela Ionescu (D)

Department of Anesthesia and Intensive Care I, University of Medicine and Pharmacy "Iuliu Hatieganu" , Cluj-Napoca, Romania; Anesthesia and Intensive Care Department, Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; Outcome Research Consortium Department Cleveland, USA. dionescuati@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH